Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
410.147786446
InChI
InChI=1S/C22H22N2O6/c1-27-17-14-18(28-2)24-21(23-17)30-19(20(25)26)22(29-3,15-10-6-4-7-11-15)16-12-8-5-9-13-16/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
InChI Key
InChIKey=FEJVSJIALLTFRP-LJQANCHMSA-N
IUPAC Name
(2S)-2-[(4,6-dimethoxypyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
Traditional IUPAC Name
darusentan
SMILES
COC1=CC(OC)=NC(O[C@H](C(O)=O)C(OC)(C2=CC=CC=C2)C2=CC=CC=C2)=N1
pKa (strongest acidic)
3.2
pKa (Strongest Basic)
-0.17
Refractivity
108.54 m3·mol-1
Dược Lực Học :
Darusentan is a selective endothelin ETA receptor antagonist.
Cơ Chế Tác Dụng :
Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
The mode of action by which the endothelin receptor antagonists cause a decrease of the BP is not yet totally elucidated; however, peripheral vasodilatation due to blockade of the vasoconstrictor effects of endothelin is the most likely explanation. A reduction of cardiac contractility is considered unlikely. Several studies have been published that investigated the effects of either selective or nonselective endothelin receptor blockade in patients with heart failure. In these studies, application of endothelin antagonists, while decreasing both systemic and pulmonary BP increased cardiac index and did not alter cardiac contractility or heart rate.
Chỉ Định :
For the treatment of congestive heart failure and hypertension.